Matrix metalloproteinases proteolyze RAB proteins and contribute to cisplatin-induced ototoxicity

This study reveals that cisplatin-induced ototoxicity is driven by the activation of MMP-2 and MMP-9, which cleave RAB proteins like RAB9A to disrupt intracellular trafficking, thereby identifying MMP-2 as a promising therapeutic target for preventing cisplatin-induced hearing loss.

The Gist

The Big Picture: The "Double-Edged Sword" Drug

Imagine Cisplatin as a highly skilled, but very aggressive, security guard hired to stop a burglar (cancer). This guard is incredibly effective at finding the burglar and neutralizing them, which is why it saves so many lives.

However, this guard has a nasty habit: while hunting the burglar, they accidentally smash up the house next door (the inner ear). This causes permanent hearing loss, a condition known as ototoxicity. For a long time, doctors have known that this happens, but they didn't fully understand how the guard was breaking the house down, leaving them with few tools to stop it without also letting the burglar escape.

The New Culprit: The "Demolition Crew" (MMPs)

This study discovered that the real damage isn't just done by the guard (Cisplatin) directly. Instead, Cisplatin triggers a hidden Demolition Crew inside the ear cells called Matrix Metalloproteinases (MMPs), specifically MMP-2 and MMP-9.

Think of these MMPs as a team of tiny, angry construction workers who usually help repair walls. But when Cisplatin creates a chaotic, stressful environment (oxidative stress), these workers go rogue. They start tearing down the internal support beams of the ear cells instead of fixing them.

The Mechanism: Cutting the "Traffic Controllers"

The researchers found something fascinating about what these rogue workers are cutting. They are targeting a specific group of proteins called RAB proteins.

The Analogy:
Imagine the inside of an ear cell is a busy city.

• RAB proteins are the traffic controllers and delivery drivers. They make sure packages (like waste, nutrients, and even the drug Cisplatin itself) get to the right place.
• When the Demolition Crew (MMPs) gets activated by Cisplatin, they start chopping up the traffic controllers.

The Result:
Without traffic controllers, the city gridlock.

1. Trash piles up: The cell can't get rid of toxic waste.
2. The drug gets stuck: The cell can't pump the Cisplatin out, so the drug stays inside longer and causes more damage.
3. The cell dies: The chaos leads to the cell committing suicide (apoptosis), resulting in hearing loss.

The Solution: The "Brakes"

The researchers tested a new strategy: What if we put the brakes on the Demolition Crew?

They used special inhibitors (chemicals like ARP-100 and ONO-4817) that act like a "Do Not Disturb" sign for the MMPs.

• In the Ear: When they added these inhibitors, the traffic controllers (RAB proteins) stayed safe. The cell didn't get clogged up, inflammation went down, and the ear cells survived the Cisplatin attack.
• In the Cancer: Crucially, they tested if stopping the Demolition Crew would help the burglar (cancer) escape. The answer was no. The inhibitors didn't stop Cisplatin from killing the cancer cells; in fact, in some tests, the cancer cells died even faster when the inhibitors were present.

Why This Matters

This is a game-changer for two reasons:

1. It solves a mystery: We finally know how Cisplatin destroys hearing cells (by cutting up the traffic controllers via MMPs).
2. It offers a dual benefit: We might be able to give patients a "shield" (the MMP inhibitor) that protects their hearing without making the cancer treatment less effective. It's like giving the security guard a shield so they can do their job without accidentally destroying the neighborhood.

The Bottom Line

This study suggests that by simply turning off a specific enzyme (MMP-2) that gets triggered by Cisplatin, we can save the delicate hair cells in our ears. It's like realizing the house wasn't destroyed by the fire itself, but by the firefighters' hoses, and now we have a way to turn down the water pressure without stopping the fire from being put out.

Technical Summary

1. Problem Statement

Cisplatin is a cornerstone chemotherapeutic agent for various solid tumors but is limited by severe, permanent ototoxicity (hearing loss) in 40–80% of patients, particularly children. The current mechanism of injury involves oxidative stress (Reactive Oxygen and Nitrogen Species, RONS) leading to hair cell death and inflammation. While the role of RONS is well-established, the specific contribution of Matrix Metalloproteinases (MMPs)—specifically MMP-2 and MMP-9, which are activated by oxidative stress—remains unclear. Furthermore, existing otoprotective strategies (e.g., sodium thiosulfate) have limitations regarding patient eligibility and efficacy. This study investigates whether MMP-2 and MMP-9 drive cisplatin-induced hair cell injury and identifies the molecular substrates responsible for this damage.

2. Methodology

The study employed a multi-faceted approach combining in vitro cell culture, proteomics, in silico modeling, and in vivo zebrafish xenograft models.

• Cell Models:
  • HEI-OC1: A murine inner ear hair cell line used to model cisplatin toxicity.
  • SF-188 & A549: Human glioblastoma and lung carcinoma cell lines used to test if MMP inhibition compromises anti-cancer efficacy.
• Interventions:
  • Cisplatin Treatment: Cells were exposed to varying concentrations (20–100 μM) and timepoints (1–48 hours).
  • Pharmacological Inhibition: Use of MMP-2 preferring inhibitors (ARP-100 and ONO-4817).
  • Genetic Manipulation: siRNA knockdown of Mmp-9 and overexpression of Mmp-2 via plasmid transfection.
• Analytical Techniques:
  • Gelatin Zymography: To measure MMP-2 and MMP-9 enzymatic activity in conditioned media and intracellular fractions (cytosolic/mitochondrial).
  • RT-qPCR & Immunofluorescence: To quantify gene expression (including Ifit-1 as a marker for N-terminal truncated MMP-2) and visualize protein localization.
  • Proteomics (DIA LC-MS/MS): Data-Independent Acquisition mass spectrometry to identify global proteome changes and potential MMP substrates.
  • In Vitro Proteolysis: Incubation of recombinant RAB9A with recombinant MMP-2 to confirm direct cleavage.
  • In Silico Analysis: Use of ProsperousPlus to predict MMP-2 cleavage sites on RAB9A and mapping onto 3D crystal structures.
  • Zebrafish Xenograft: A549-mCherry cells injected into zebrafish larvae to assess tumor burden reduction under cisplatin treatment with and without ARP-100.
• Assays: MTT (viability), Flow Cytometry (apoptosis/Annexin V), ELISA (IL-6 secretion).

3. Key Contributions

• Novel Mechanism Identification: First demonstration that cisplatin activates both full-length and N-terminal truncated (NTT) intracellular isoforms of MMP-2 and MMP-9 in auditory hair cells.
• Substrate Discovery: Identification of RAB proteins (specifically RAB9A) as direct substrates of MMP-2, linking protease activity to the disruption of intracellular trafficking.
• Therapeutic Validation: Demonstration that MMP-2 inhibition protects hair cells without compromising cisplatin's anti-tumor efficacy, suggesting a dual-benefit therapeutic strategy.

4. Key Results

A. Activation of MMPs by Cisplatin

• Temporal Activation: Cisplatin exposure rapidly increased intracellular MMP-2 activity (within 4–6 hours) and secreted MMP-9 activity (detectable at 24–48 hours).
• Isoform Specificity: Cisplatin induced the expression of the N-terminal truncated MMP-2 (NTT-MMP-2), an intracellular isoform lacking the prodomain. This was evidenced by the upregulation of Ifit-1 (a known downstream target of NTT-MMP-2), which was reversed by the MMP-2 inhibitor ARP-100.
• Localization: Increased MMP-2 and MMP-9 activity was observed in the cytosol and nucleus, but not significantly in mitochondria.

B. Role in Cytotoxicity and Inflammation

• Cell Survival: Pharmacological inhibition of MMP-2 (using ARP-100 or ONO-4817) significantly increased the IC50 of cisplatin in HEI-OC1 cells, indicating reduced toxicity.
• Apoptosis: MMP-2 inhibition reduced cisplatin-induced apoptosis by ~56% (measured by Annexin V/PI staining).
• Inflammation: MMP-2 overexpression synergized with cisplatin to increase IL-6 secretion. Conversely, MMP-2 inhibition or Mmp-9 knockdown (via siRNA) significantly reduced cisplatin-induced IL-6 levels, linking MMPs to the inflammatory cascade driving cell death.

C. Proteomic Analysis and RAB Degradation

• Proteome Shift: Mass spectrometry revealed that cisplatin downregulated proteins involved in intracellular trafficking, cell cycle, and mitochondrial organization.
• MMP-2 Dependence: Many of these downregulated proteins were restored when MMP-2 was inhibited. Gene Ontology (GO) analysis highlighted intracellular trafficking as a primary affected pathway.
• RAB Family: 20 members of the RAB GTPase family were downregulated by cisplatin. MMP-2 inhibition partially restored their abundance.
• Direct Cleavage: In vitro assays confirmed that recombinant MMP-2 directly cleaves RAB9A (a regulator of endosome-to-Golgi transport). In silico analysis predicted specific cleavage sites (e.g., Lys45, Ile121) within functional domains of RAB9A.

D. Preservation of Anti-Cancer Efficacy

• In Vitro: MMP-2 inhibitors did not reduce the cytotoxicity of cisplatin in SF-188 (glioblastoma) or A549 (lung cancer) cells.
• In Vivo (Zebrafish): In a zebrafish xenograft model, the combination of cisplatin and ARP-100 resulted in the lowest tumor burden (41 cells/larva) compared to cisplatin alone (75 cells/larva) or vehicle (126 cells/larva). This suggests MMP-2 inhibition may actually enhance cisplatin's therapeutic effect in cancer models.

5. Significance and Implications

• Mechanistic Insight: The study uncovers a previously unrecognized mechanism of cisplatin ototoxicity: the proteolytic degradation of RAB proteins by intracellular MMP-2. This disruption likely impairs vesicular trafficking, preventing the efficient export of cisplatin from hair cells and exacerbating intracellular accumulation and damage.
• Therapeutic Potential: MMP-2 inhibitors (like ARP-100) represent a promising class of otoprotectants. Unlike current options, they target a specific proteolytic pathway rather than just scavenging ROS.
• Dual Benefit: Crucially, the study addresses the major concern of otoprotectants interfering with chemotherapy. The data suggests that inhibiting MMP-2 protects the ear while maintaining or even enhancing the anti-tumor efficacy of cisplatin.
• Future Directions: The findings propose a "dual-action" strategy where targeting MMPs could simultaneously mitigate hearing loss and suppress tumor metastasis (given MMPs' role in metastasis), warranting further validation in mammalian cancer models.

In conclusion, this paper establishes MMP-2 as a critical mediator of cisplatin-induced hair cell death via the degradation of trafficking proteins (RABs) and inflammation, positioning MMP-2 inhibitors as a viable, safe, and potentially synergistic therapeutic strategy for preventing chemotherapy-induced hearing loss.